drug
galcanezumab
Marketedupdated 5mo agoby Eli Lilly and Co
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying galcanezumab
- phase4Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
- phase3A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
- phase4Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
- phase3A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
- —Emgality for Migraine in Breastmilk
- phase4The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
- phase2Galcanezumab for Vestibular Migraine
- phase4A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
News(3)
- New guidelines on migraine prevention reflect increasing options for patients“There has been a wealth of new treatment available” for migraine prevention, said a co-author of new guidelines released Monday.stat · 1mo ago
- Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsSlate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead c…fiercebiotech · 1mo ago
- Study data convince Lundbeck to push new migraine drug forwardA possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.biopharma_dive · 3mo ago
Data sources
last refreshed 48m ago
Found something off?
comments(0)
5-min edit window · permanent after that